Abstract
The potential of α-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of α-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with α-particle emitters. Although α-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted α-particle emitter therapy and to provide guidance and recommendations for human α-particle emitter dosimetry.
Footnotes
-
↵* Unabridged version of this document is available at: http://interactive.snm.org/index.cfm?PageID=1110&RPID=2199&FileID=144234.
-
COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.
Jump to section
Related Articles
Cited By...
- 225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer
- Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
- Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
- Simulating Alpha Particle Doses at the Micron Scale from Prostate Cancer Patient Derived Bone Metastatic Biopsies Using GATE
- Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
- Glioblastoma Treatment by Systemic Actinium-225 {alpha}-particle Dendrimer-radioconjugates is Improved by Chemotherapy
- The MIRD Schema for Radiopharmaceutical Dosimetry: A Review
- [225Ac]Ac/[89Zr]Zr-labeled N4MU01 radioimmunoconjugates as theranostics against nectin-4 positive triple negative breast cancer
- Beyond Average: {alpha}-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
- Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
- Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
- Efficacy of HER2-Targeted Intraperitoneal 225Ac {alpha}-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
- Combined, yet Separate: cocktails of carriers (not drugs) for {alpha}-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers
- Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
- Evaluation of Candidate Theranostics for 227Th/89Zr Paired Radioimmunotherapy of Lymphoma
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single-Domain Antibody Fragment
- From Concept to Regulatory Drug Approval: Lessons for Theranostics
- Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer
- Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered {alpha}-Particles May Realize the Promise for 225Ac in Large, Solid Tumors
- Glypican-3-Targeted 227Th {alpha}-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
- Harnessing {alpha}-Emitting Radionuclides for Therapy: Radiolabeling Method Review
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical {alpha}-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
- TAG-72-Targeted {alpha}-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody
- 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models
- PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
- Patients Resistant Against PSMA-Targeting {alpha}-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes
- Cellular and Genetic Determinants of the Sensitivity of Cancer to {alpha}-Particle Irradiation
- Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
- Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
- Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
- {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 1
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated {alpha}-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
- 225Ac-PSMA-617 for PSMA-Targeted {alpha}-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma
- Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide 177Lu Compared to Alpha Particles and Gamma Rays
- {alpha}-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation
- A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
- Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for {alpha}-Particle Radioimmunotherapy of Cancer
- MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
- Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: {alpha} Therapy with 223Ra-Dichloride
- Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular {alpha}-Particle Therapy of Cancer
- Immunoliposomal Delivery of 213Bi for {alpha}-Emitter Targeting of Metastatic Breast Cancer